IL1A and familial Mediterranean fever: Anti-IL-1 agents were evaluated as well in Basaran et al. study in which eight pediatric FMF patients were considered refractory to colchicine because of the continuous severe attacks even after having the maximum colchicine dose (2 mg/day) (115).